Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c01765 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Lianchao Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, no. 345 Lingling Road., Shanghai 2000…. Hauptthemen laut MEDLINE: Histone-Lysine N-Methyltransferase, Proteolysis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Howard Hughes Medical Institute, National Cancer Institute.
Abstract (Originalsprache)
Nuclear receptor-binding SET domain-containing 2 (NSD2), a methyltransferase that primarily installs the dimethyl mark on lysine 36 of histone 3 (H3K36me2), has been recognized as a promising therapeutic target against cancer. However, existing NSD2 inhibitors suffer from low activity or inferior selectivity, and none of them can simultaneously remove the methyltransferase activity and chromatin binding function of NSD2. Herein we report the discovery of a novel NSD2 degrader LLC0424 by leveraging the proteolysis-targeting chimera technology. LLC0424 potently degraded NSD2 protein with a DC50 value of 20 nM and a Dmax value of 96% in acute lymphoblastic leukemia (ALL) RPMI-8402 cells. Mechanistic studies revealed LLC0424 to selectively induce NSD2 degradation in a cereblon- and proteasome-dependent fashion. LLC0424 also caused continuous downregulation of H3K36me2 and growth inhibition of ALL cell lines with NSD2 mutation. Importantly, intravenous or intraperitoneal injection of LLC0424 showed potent NSD2 degradation in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, no. 345 Lingling Road., Shanghai 200032, People's Republic of China.
- Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Urology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Cancer Biology Program, University of Michigan, Ann Arbor, Michigan 48109, United States.
ORCID-Profile: Fengtao Zhou, Zhen Wang, Ke Ding
Förderung
- NCI NIH HHS
- Howard Hughes Medical Institute
- National Cancer Institute
- Shenzhen Bay Laboratory
- Shanghai Key Laboratory of Chemical Biology
- American Cancer Society
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Liu, L., Parolia, A., Liu, Y., Hou, C., He, T., Qiao, Y., Eyunni, S., Luo, J., Li, C., Wang, Y., Zhou, F., Huang, W., Ren, X., Wang, Z., Chinnaiyan, A. M., & Ding, K. (2024). Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01765
Vancouver
Liu L, Parolia A, Liu Y, Hou C, He T, Qiao Y, et al. Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01765
BibTeX
@article{Liu2024,
author = {Liu, Lianchao and Parolia, Abhijit and Liu, Yihan and Hou, Caiyun and He, Tongchen and Qiao, Yuanyuan and Eyunni, Sanjana and Luo, Jie and Li, Chungen and Wang, Yongxing and Zhou, Fengtao and Huang, Weixue and Ren, Xiaomei and Wang, Zhen and Chinnaiyan, Arul M and Ding, Ke},
title = {Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c01765}
}
EUVIMED